BioStock: AACR puts spotlight on personalised cancer vaccines

Moderna generated a lot of buzz after reporting clinical data with its personalised mRNA cancer vaccine at AACR. Also showcasing its own personalised cancer immunotherapy at the conference was Evaxion Biotech, which presented promising phase I/II data with its candidate EVX-02. BioStock spoke with Evaxion’s Chief Scientific Officer Birgitte Rønø to learn more about how Evaxion plans on impacting the cancer immunotherapy landscape.

Read the interview with Birgitte Rønø at biostock.se:

AACR puts spotlight on personalised cancer vaccines - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/